Medicare ESA Policy May Find Support In FDA Letter But J&J Sees Differently
Executive Summary
Key Democratic legislators are spotlighting an FDA letter on erythropoiesis-stimulating agents as indicating agreement between FDA and Medicare policies, but some stakeholders interpret it as pointing out differences between the agencies
You may also be interested in...
Antidepressants’ Revised Med Guides Is A Step Backward – Rep. Ferguson
A United States Congressman wants FDA to revert back to language that was contained in previous medication guides regarding antidepressant agents and the risk of suicide in children
CMS May Have Unlikely Ally In Rep. Stark As Interest In ESA Coverage Grows
Rep. Pete Stark, D-Calif., who in the past has been openly critical of how CMS covers erythropoiesis-stimulating agents for Medicare beneficiaries, may be a key ally for the agency as it fends off increased pressure from both Congress and industry stakeholders to reconsider its national coverage determination limiting coverage of ESAs in the non-renal setting
Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
Commercial insurers are unlikely to follow CMS' recent national coverage determination on erythropoiesis-stimulating agents for non-renal disease uses, Amgen is predicting